The Cell and Gene Therapy Advisory Committee was established to highlight the value of cell and gene therapies to patients and the wider UK economy and to promote the UK’s global role in delivering these transformative treatments and the innovative science behind them.

The committee brings together the majority of the UK’s regenerative medicine industry, with over 30 UK companies (SMEs and big pharma) and key organisations including the Cell and Gene Therapy Catapult, and the Knowledge Transfer Network (KTN) and Innovate UK as members.

2020 priorities


  • Promote UK excellence in Cell and Gene Therapies both internationally and with UK policymakers
  • Build on strong partnerships with ARM, FIRM and Phacilitate and seek opportunities to engage with other coalitions
  • Build connections with the regulatory environment, including the MHRA and the British Pharmacopeia


  • Develop an ongoing report series in collaboration with ARM on the ATMP landscape in the UK to highlight the UK’s leading position in CGT
  • Contribute to the development of the Innovation Office and the UK’s global CGT offering
  • Support BIA engagement with Ministers and their advisers, keeping CGT central to government policy

Expert advice

  • Input to the development of measurements and standards for CGT via the MHRA, the National Measurement System, the British Standards Institute and the Standards Coordinating Body.
  • Feed into government-led activity related to CGT, such as patient registries, skills and training
  • Respond to opportunities to engage on NHS access and reimbursement policies for CGT, including those presented by the Accelerated Access Collaborative, the NICE Methods Review and other programmes

Committee Chair: Dr Sven Kili, Principal, Sven Kili Consulting

Committee Vice-Chair: Helen Delahaye, Consulting Chief Operating Officer, Azellon

For more information contact Rosie Lindup, Policy and Public Affairs Manager

Member list

Advanced Centre for Biochemical Engineering, University College London

The Advanced Centre for Biochemical Engineeering hosts the MBI® Modular Training Programme for the Bioindustries.

Anthony Nolan

Anthony Nolan is the UK's stem cell transplant charity. We recruit donors and match them to patients with blood cancers and blood disorders in need of a lifesaving transplant. We provide information and support to patients and families, and advocate on their behalf. Our research institute aims to improve the outcomes of transplant and forge collaborations with organisations in the cellular therapy field to pioneer new approaches to treatment.

Arnold & Porter Kaye Scholer LLP

Arnold & Porter is a leading international law firm headquartered in Washington DC with a number of other offices nation-wide in the US including in New York and with a rapidly growing presence in London.


Autolus Ltd

Autolus is biotechnology company focussed on the development and commercialisation of engineered T-cell therapies for haematological and solid tumours.

Azellon Ltd

Azellon is a spin-out company from The University of Bristol focused on the development and commercialisation of a platform technology using mesenchymal stem cells infused into a biological scaffold for tissue repair - the Cell Bandage.

Biodivide Ltd

Biodivide has the vision to transform the regenerative medicine field by addressing challenges in the complete workflow from stem cell harvest, manufacture, cryostorage to clinical administration.

Boult Wade Tennant

Intellectual Property Law firm with expertise in Biotechnology and Life Sciences, Chemical and Materials, Engineering and Designs, High Tech and Electrical and, Trade Mark and Domain Names.

Bristows LLP

Bristows is a dynamic and globally recognised law firm based in London with a client base that comes from a wide range of industries and includes some of the world’s leading companies.

Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation.

Cobra Biologics

Cobra provides a comprehensive biopharmaceuticals service offering, with multi-functional project teams nurturing products from pre-clinical to commercial scale GMP manufacture.

eXmoor Pharma Concepts Ltd

eXmoor pharma is a technical and strategic consultancy in biopharmaceuticals, secondary pharmaceuticals and cell & gene therapies. We work in capital projects and GMP biomanufacturing.


Field Fisher Waterhouse is a European law firm providing commercial solutions across a range of industry sectors. We have a particular focus on companies that are highly regulated and those with intellectual property and technology driven business models.

GE Healthcare UK Ltd

GE is a global infrastructure, finance and media company taking on the world's toughest challenges.

Gilead Sciences Ltd

Horizon Discovery

Horizon is a revenue-generating life science group supplying research tools to organizations engaged in translational genomics research and the development of personalized medicines.

Innovate UK

Knowledge Transfer Network


LGC is an international science-based company and market leader in analytical, forensic, biotechnology, diagnostic and product services and reference standards.


LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients.

Miltenyi Biotec Ltd

Moorfields Eye Hospital Biomedical Research Centre

Moorfields Pharmaceuticals is the manufacturing arm of Moorfields Eye Hospital NHS Foundation Trust. We produce nearly 100 ophthalmic specials and have a growing portfolio of branded licensed products.

NHS Blood and Transplant

NHS Blood and Transplant
NHSBT is uniquely positioned to support the exciting developments taking place in cell and gene therapies. Through our experience in leucapheresis, processing and storage of stem cells for transplant and GMP manufacture of clinical grade cellular and molecular therapies, combined with our strong links to clinicians and hospitals, we help develop and deliver new advanced treatments to the bedside.


Orchard Therapeutics

Oxford BioMedica plc

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.


Expert global consultancy specialising in access for orphan drugs.

ReNeuron Group Plc

ReNeuron are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Roslin Cell Therapies

Roslin Cells are world leaders in the isolation of new clinical grade pluripotent stem cells for use in research and therapy.

Sarepta Therapeutics

Sarepta Therapeutics is a commercial stage biopharmaceutical company developing RNA targeted and Gene therapies for rare neuromuscular diseases.

Sartorius Stedim Biotech

Sven Kili


Sven Kili Consulting Ltd

Dr Sven Kili is currently principle at Sven Kili Consulting Ltd. Where he provides specialist strategic advice to Regenerative Medicine companies. He was previously the VP and Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases where he led teams developing ex-vivo Gene Therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo gene therapy to be approved for children with ADA-SCID; Wiskott - Aldrich syndrome (WAS); Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development and medical affairs activities culminating in the granting of the first combined ATMP approval in the EU for MACI®. His team also prepared and submitted Advanced Therapy regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US. Before joining Genzyme, Sven worked for Geistlich Pharma where, in addition to leading the cell therapy activities, he oversaw all UK & Irish regulatory functions and was the QPPV for pharmacovigilance for the EU. Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy in clinical development, regulatory compliance, value creation, risk management and product safety,


Synthace is an applied synthetic biology company which bioengineers micro-organisms for the production of high value chemical products.

Thermo Fisher Scientific

Thermo Fisher Scientific is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.